AbClon Inc is a Korea-based company principally engaged in the development, manufacture and distribution of antibody drug. The Company developed a bio synergy antibody, a therapeutic antibody for a new mechanism that is different from conventional therapeutic agents, and is based on the YPLUS and AffiMab platforms. The company's products include AC101, AC103, AC104, AC106, AC203, AM201, AM101, AM102 and AM103. The Company distributes its products within domestic market and to overseas markets.

Employees

Sector

Pharmaceuticals

More about the company

Quotes

Date	Price	Change	Volume
15/26/15	₩22,850.00	+6.78%	1,36,064
14/26/14	₩21,400.00	-5.52%	1,93,265
13/26/13	₩22,650.00	-3.62%	99,052
10/26/10	₩23,500.00	+3.75%	96,892
09/26/09	₩22,650.00	-1.95%	91,720

End-of-day quote Korea S.E.

More quotes

Income Statement and Estimates

More financial data

End-of-day quote Korea S.E. Other stock markets 15/07/2026			5-day change	1st Jan Change
22,850.00 ^KRW	+6.78%		-1.08%	-46.24%

08/06	Alligator partner Henlius doses first patients in HLX22 study	FW
22/05	Alligator Bioscience comments on Henlius update for HLX22	FW

Market Cap	46TCr 31Cr 27Cr 25Cr 23Cr 43Cr 2.94TCr 44Cr 294.67Cr 115.62Cr 1.44TCr 114.93Cr 112.41Cr 4.96TCr	P/E 2024	-14.5x	P/E 2025	-43.5x
Enterprise Value	42TCr 28Cr 25Cr 23Cr 21Cr 39Cr 2.7TCr 40Cr 270.15Cr 106Cr 1.32TCr 105.37Cr 103.06Cr 4.55TCr	EV / Sales 2024	103x	EV / Sales 2025	164x
Free-Float	80.52%	Yield 2024 *	-	Yield 2025	-

08/06	Alligator partner Henlius doses first patients in HLX22 study	FW
22/05	Alligator Bioscience comments on Henlius update for HLX22	FW
23/04	Alligator partner Henlius presents preclinical data for HLX49	FW
23/04	Alligator Bioscience Announces Preclinical Data Presentation of Hlx49 Antibody?Drug Conjugate	CI
07/04	Abclon wins 396 million won order	RE
09/03	AbClon wins 778 million won order	RE
02/03	Alligator Bioscience: First Patient Dosed in Phase 2/3 Study with HLX22 in China	FW
01/25/01	AbClon Inc. announced that it expects to receive KRW 35.999952065 billion in funding from Paratus Investment Inc., Dongyu Investment Co., Ltd, Winvest Venture Capital and other investors.	CI
27/25/27	Abclon wins 309 million won order	RE
20/25/20	Abclon Wins 354 Million Won Order	RE
19/25/19	AbClon Inc To Issue 1.4 Million Common Shares	RE
19/25/19	AbClon Inc. announced that it has received KRW 12.2122 billion in funding from Chong Kun Dang Pharmaceutical Corp.	CI
15/25/15	Abclon Wins 307 Million Won Order	RE

08/06	Alligator Bioscience comments on Henlius update on global phase 3 trial with HLX22	AQ
22/05	Alligator Bioscience comments on Henlius update on long-term follow-up data for HLX22	AQ
23/04	Alligator Bioscience comments on Henlius presentation of HLX49 preclinical data at AACR 2026	AQ
02/03	Alligator Bioscience comments on Henlius dosing first patient in Phase 2/3 breast cancer study of HLX22	AQ
04/24/04	Alligator Announces First Patient Dosed in Shanghai Henlius Biotech, Inc. Phase 3 Clinical Trial	AQ

AbClon Inc. Share Price

Stocks

A174900

KR7174900001

Pharmaceuticals

Valuation: AbClon Inc.

Chart: AbClon Inc.

Latest news : AbClon Inc.

Press Releases: AbClon Inc.

Quotes and Performance

Course Extremes

Managers and Directors: AbClon Inc.

Biopharmaceuticals

Financials

Company Profile

Quotes

Income Statement and Estimates

1 day	+6.78%
1 week	-1.08%
Current month	-17.81%
1 month	-28.03%
3 months	-56.72%
6 months	-59.05%
Current year	-46.24%

1 week	20,300	25,100
1 month	20,300	36,850
Current year	20,300	95,800
1 year	9,770	95,800
3 years	6,810	95,800
5 years	6,810	95,800
10 years	6,810	95,800

Manager	Title	Age	Since
Jong-Seo Lee CEO	Chief Executive Officer	63	25/06/2010
Doo-Hun Kim DFI	Director of Finance/CFO	58	28/03/2024
Jong-Hoon Kim CTO	Chief Tech/Sci/R&D Officer	57	29/03/2023

Director	Title	Age	Since
Jong-Seo Lee BRD	Director/Board Member	63	-
Jung-Ho Kim BRD	Director/Board Member	62	29/03/2021
Doo-Hun Kim BRD	Director/Board Member	58	28/03/2024

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ABCLON INC.	+6.78%	-1.08%	+105.86%	+46.01%	31Cr
REGENERON PHARMACEUTICALS, INC.	+1.27%	+0.24%	+21.26%	-7.53%	6.76TCr
UCB	+1.38%	-5.23%	+38.08%	+197.15%	5.13TCr
SAMSUNG BIOLOGICS CO.,LTD.	+1.10%	+38.30%	+38.30%	+38.30%	4.3TCr
CSL LIMITED	+0.62%	-2.41%	-50.50%	-52.67%	4.08TCr
BIOGEN INC.	+2.76%	-1.56%	+54.70%	-29.29%	2.91TCr
MODERNA, INC.	+1.25%	-7.48%	+116.21%	-43.73%	2.71TCr
INCYTE CORPORATION	+0.18%	-1.85%	+68.63%	+86.35%	2.3TCr
INNOVENT BIOLOGICS, INC.	-3.35%	+8.69%	+8.87%	+197.94%	2.16TCr
BRIDGEBIO PHARMA, INC.	-1.70%	+5.53%	+76.00%	+353.68%	1.62TCr
Average	+1.03%	+0.46%	+47.74%	+78.62%	3.2TCr
Weighted average by Cap.	+0.78%	-0.30%	+33.60%	+59.58%

	2024	2025
Net sales	233.98Cr 15.71L 13.73L 12.67L 11.64L 22.06L 15Cr 22.44L 1.51Cr 59.34L 7.39Cr 58.98L 57.69L 25Cr	471.41Cr 31.64L 27.67L 25.52L 23.46L 44.45L 30Cr 45.21L 3.05Cr 1.2Cr 15Cr 1.19Cr 1.16Cr 51Cr
Net income	-1.63TCr -1.09Cr -95.67L -88.25L -81.13L -1.54Cr -105.29Cr -1.56Cr -11Cr -4.13Cr -51Cr -4.11Cr -4.02Cr -177.38Cr	-1.79TCr -1.2Cr -1.05Cr -96.95L -89.12L -1.69Cr -115.66Cr -1.72Cr -12Cr -4.54Cr -57Cr -4.51Cr -4.42Cr -194.85Cr
Net Debt	-461.19Cr -30.96L -27.07L -24.97L -22.95L -43.49L -30Cr -44.23L -2.98Cr -1.17Cr -15Cr -1.16Cr -1.14Cr -50Cr	-3.79TCr -2.55Cr -2.23Cr -2.05Cr -1.89Cr -3.58Cr -244.96Cr -3.64Cr -25Cr -9.62Cr -119.73Cr -9.56Cr -9.35Cr -412.67Cr